ClinConnect ClinConnect Logo
Search / Trial NCT06401161

Study on the Effect of 3T Pu'er Tea in Regulating Glucose and Lipid Metabolism

Launched by LONGGANG DISTRICT PEOPLE'S HOSPITAL OF SHENZHEN · May 2, 2024

Trial Information

Current as of August 20, 2025

Enrolling by invitation

Keywords

Pu' Er Tea Glucose And Lipid Metabolism Intestinalflora

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • The A、B should be simultaneously met, or combined with the C、D、E.
  • 1. 18-65 years, priority for patients over 30 years;
  • 2. Overweight / obese patients: BMI ≥24 kg/m2.
  • 3. Or combined with nonalcoholic fatty liver disease: determined by the hospital MRI nuclear magnetic quantification;
  • 4. Or combined with dyslipidemia: blood total cholesterol TC≥6.4mmol/L or blood total triglyceride TG≥2.0mmol/L or blood low-density lipoprotein LDL-C≥3.1mmol/L;
  • 5. Or with abnormal blood glucose:
  • Impaired fasting glucose, IFG: fasting blood glucose was 6.1\~\<7.0mmol/L,and 2 hours after 75g oral blood glucose tolerance test(OGTT) \<7.8mmol / L.
  • Impaired glucose tolerance, IGT: the fasting blood glucose was \<6.1mmol/L and 2 hours after 75gOGTT was 7.8\~ \<11.1 mmol / L;
  • IFG with IGT: patients with both IFG and IGT;
  • Patients with type 2 diabetes: random blood glucose 11.1mmol/L or fasting glucose of 7.0 mmol/L or 2 hours after OGTT.
  • Exclusion Criteria:
  • 1. Type 2 diabetes and insulin injections or oral hypoglycemic drugs and other special types of diabetes.
  • 2. For women during pregnancy or lactation or with allergies;
  • 3. Patients treated with any hypoglycemic drugs and insulin injections; regular or planned patients taking drugs that may affect glucose and lipid metabolism (as judged by clinicians, such as diet pills, lipid-lowering drugs) and liver protection drugs (as judged by clinicians);
  • 4. Patients with severe cardiovascular diseases, cerebrovascular diseases, liver, kidney, and hematopoietic diseases;
  • 5. Combined with other infectious diseases, such as hepatitis A, hepatitis B, hepatitis C, and acquired immunodeficiency syndrome;
  • 6. Take probiotics, prebiotics, antioxidants and fish oil nutrient supplements within 3 months;
  • 7. Current smokers and regular drinking (excluding social drinkers only);
  • 8. Yogurt intake within 1 week before the first visit and antibiotics within 3 months;
  • 9. Drink strong tea regularly;
  • 10. Participate in other clinical trials within 3 months;
  • 11. Unable not cooperate with the investigator for other reasons.
  • 12. Unfit for the researcherr.

About Longgang District People's Hospital Of Shenzhen

Longgang District People's Hospital of Shenzhen is a leading healthcare institution dedicated to providing high-quality medical services and advancing clinical research in the Longgang District of Shenzhen, China. With a commitment to innovation and excellence in patient care, the hospital plays a pivotal role in the development and management of clinical trials aimed at improving health outcomes. Leveraging a multidisciplinary team of healthcare professionals and state-of-the-art facilities, the hospital fosters a collaborative environment for researchers and clinicians to explore new therapeutic interventions and contribute to the global body of medical knowledge. Through its rigorous adherence to ethical standards and regulatory compliance, Longgang District People's Hospital of Shenzhen is positioned as a trusted sponsor in the clinical research landscape.

Locations

Shenzhen, Guangdong, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported